Diagnostic Systems buys Oxford Bio-Innovation:
This article was originally published in Clinica
Executive Summary
Webster, Texas-based Diagnostic Systems Laboratories (DSL) has bought UK company Oxford Bio-Innovation (OBI), a joint venture between Oxford Brookes University and Serotec. The venture, which was set up in 1998, develops diagnostic and research products for the measurement of Inhibin and Activin levels, which are related to male infertility, assessment of ovarian reserve, prediction and IVF outcomes and differential diagnosis of ovarian cancer. DSL is active in reproductive endocrinology and sells its products in over 80 countries worldwide. Serotec UK supplies high quality antibodies and immunological reagents for laboratory and production processing.